Inozyme Pharma, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 4 | -$0.40 | -$0.40 | -$0.40 |
| Q2 2024 | 8 | -$0.46 | -$0.41 | -$0.44 |
| Q3 2024 | 4 | -$0.44 | -$0.44 | -$0.44 |
| Q1 2025 | 4 | -$0.46 | -$0.46 | -$0.46 |
| Q2 2025 | 5 | -$0.44 | -$0.44 | -$0.44 |
| Q3 2025 | 4 | -$0.44 | -$0.44 | -$0.44 |
| Q4 2025 | 5 | -$0.44 | -$0.44 | -$0.44 |
Inozyme Pharma, Inc. Earnings Date And Information
Inozyme Pharma, Inc. last posted its earnings results on Tuesday, August 6th, 2024. The company reported $-0.44 earnings per share for the quarter, missing analysts' consensus estimates of $-0.37 by $0.07. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Inozyme Pharma, Inc. has generated $-1 earnings per share over the last year ($-1.37 diluted earnings per share) and currently has a price-to-earnings ratio of -3.01. Inozyme Pharma, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 5th, 2024 based on prior year's report dates.
Inozyme Pharma, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/06/2024 | Q2 2024 | -$0.37 | -$0.44 | -0.07 | $0 | $0 |
| 05/07/2024 | Q1 2024 | -$0.35 | -$0.38 | -0.03 | $0 | |
| 03/12/2024 | Q4 2023 | -$0.31 | -$0.35 | -0.04 | $1.98 M | |
| 11/07/2023 | Q3 2023 | -$0.32 | -$0.29 | 0.03 | $0 | |
| 08/08/2023 | Q2 2023 | -$0.43 | -$0.35 | 0.08 | $0 | |
| 05/09/2023 | Q1 2023 | -$0.44 | -$0.37 | 0.07 | $0 | |
| 03/22/2023 | Q4 2022 | -$0.46 | -$0.43 | 0.03 | $0 | |
| 11/10/2022 | Q3 2022 | -$0.43 | -$0.36 | 0.07 | $0 | |
| 08/15/2022 | Q2 2022 | -$0.48 | -$0.38 | 0.1 | $0 | |
| 05/10/2022 | Q1 2022 | -$0.81 | -$0.71 | 0.1 | $0 | |
| 03/15/2022 | Q4 2021 | -$0.73 | -$0.79 | -0.06 | $0 | |
| 11/09/2021 | Q3 2021 | -$0.61 | -$0.60 | 0.01 | $0 | |
| 08/11/2021 | Q2 2021 | -$0.57 | -$0.53 | 0.04 | $0 | |
| 05/12/2021 | Q1 2021 | -$0.54 | -$0.47 | 0.07 | $0 | |
| 03/25/2021 | Q4 2020 | -$0.55 | -$0.61 | -0.06 | $0 | |
| 11/12/2020 | Q3 2020 | -$0.51 | -$1.55 | -1.04 | $0 | |
| 09/03/2020 | Q2 2020 | -$1.41 | -$0.47 | 0.94 | $0 | |
| 03/30/2020 | Q1 2020 | -$0.51 | $0 | |||
| 12/30/2019 | Q4 2019 | -$0.43 | $0 | |||
| 09/29/2019 | Q3 2019 | -$0.27 | $0 |
Inozyme Pharma, Inc. Earnings: Frequently Asked Questions
-
When is Inozyme Pharma, Inc.'s earnings date?
Inozyme Pharma, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 5th, 2024 based off last year's report dates.
-
How can I listen to Inozyme Pharma, Inc.'s earnings conference call?
The conference call for Inozyme Pharma, Inc.'s latest earnings report can be listened to online.
-
How can I read Inozyme Pharma, Inc.'s conference call transcript?
The conference call transcript for Inozyme Pharma, Inc.'s latest earnings report can be read online.
-
How much profit does Inozyme Pharma, Inc. generate each year?
Inozyme Pharma, Inc. (:INZY) has a recorded net income of $0. Inozyme Pharma, Inc. has generated $-1.37 earnings per share over the last four quarters.
-
What is Inozyme Pharma, Inc.'s price-to-earnings ratio?
Inozyme Pharma, Inc. (:INZY) has a price-to-earnings ratio of -3.01 and price/earnings-to-growth ratio is 0.46.
